CorMedix Inc, Howmet Aerospace Inc Pref, Triple Flag Precious Metals Corp. Read The Tokenist (Timothy Fries)'s latest article on Investing.com ...

For all cases of CRBSI, if the CVC is no longer needed for management of the patient, it should be removed. Empiric antimicrobial therapy regimens for suspected CRBSI should be developed based on ...

These strategic moves are expected to enhance CorMedix's commercial opportunities and provide early validation for DefenCath's value proposition in preventing End-Stage Renal Disease-Catheter-Related ...

DefenCath, CorMedix's primary product, has been at the center of the company's recent success. The product, designed for use in outpatient settings, has shown promising signs since its launch. The ...

The most common clinical signs and symptoms of CRBSI are inflammation or purulence at the catheter site, as well as the acute onset of fever, chills, and hypotension with no other apparent source ...